Who We Are
Based in New York City and London, our dedicated team is working to fulfill our mission of ending HPV and Anal Cancer!
Justine Almada – Executive Director
Kassandra Samman – Director of Patient Services & External Relations
David Winterflood – Finance & Communications Manager
Board of Directors
Jesper Bo Hansen
Scientific Advisory Board
Cathy Eng, M.D., F.A.C.P.
Professor, Department of Gastrointestinal Medical Oncology
Director, Department of Gastrointestinal Medical Oncology
Associate Medical Director, Colorectal Center
The University of Texas M. D. Anderson Cancer Center
Cathy Eng, M.D., received her medical degree from Hahnemann University School of Medicine in Philadelphia. She completed her residency training in internal medicine at the Rush-Presbyterian St. Luke’s Medical Center in Chicago and her fellowship in hematology/oncology at the University of Chicago Medical Center. Dr. Eng serves on numerous committees for MDACC, SWOG, ACOSOG, ARCAD, and ASCO. She is the Chairman Elect for the GI Cancers Symposium Scientific Program Committee 2011 and Chairman for 2012. Dr. Eng is a key opinion leader in her field and is the principal clinical investigator on several international and national clinical trials evaluating the use of chemotherapy treatment and targeted therapy in colorectal and anal carcinomas. She has authored peer-reviewed journal articles, abstracts, and book chapters and serves as a reviewer for many leading journals such as Cancer, Clinical Cancer Research, International Journal of Radiation Oncology and Biophysics, and Journal of Clinical Oncology.
Dr. Paul A Fox, MA, F.R.C.P
Consultant Physician in HIV and GU Medicine
Paul has a long standing interest in HPV. He studied medicine at Cambridge University, graduating in 1987. He has worked at the Chelsea & Westminster Hospital since 1996, where he became concerned in the late 1990s by a rising tide of anal cancer in HIV positive patients. This led him in 1999 to study the technique of High Resolution Anoscopy at the University of California in San Francisco under Professor Joel Palefsky, and to set up his own AIN research and treatment clinic. He receives referrals to this clinic from across the United Kingdom. Publications include numerous papers and articles on HPV, AIN and anal cancer, topics which he also teaches on the national diploma course in sexual health. He is a longstanding member of the HPV special interest group of BASHH, has contributed to national guidelines on HPV management, and has worked in an advisory capacity with the National Cancer Screening Committee. He is an Honorary Senior Lecturer at Imperial College School of Medicine.
Karyn Aalami Goodman, MD, MS
Professor of Radiation Oncology
University of Colorado School of Medicine
Dr. Karyn Goodman is a Professor of Radiation Oncology at the University of Colorado School of Medicine. She specializes in treating cancers of the gastrointestinal (GI) tract. She has a B.A. in Human Biology from Stanford University and an M.S. in Epidemiology from the Harvard School of Public Health. Dr. Goodman received her medical degree from Stanford University. Following her internship in Internal Medicine at Stanford Hospital and Clinics, she completed residency training in Radiation Oncology at Memorial Sloan-Kettering Cancer Center. She was on the faculty at Stanford University in 2004-2006 in the Department of Radiation Oncology. She came back to Memorial Sloan-Kettering in 2007 to be the head of GI Radiation Oncology and began her professorship at the University of Colorado in September of 2015. She is the national study chair for an intergroup study of PET-directed therapy for Esophageal Cancer and the national radiation oncology principle investigator of the RTOG 0848 study of adjuvant chemoradiation pancreatic cancer. She is involved on national committees evaluating best practices and quality of care in radiation oncology. Dr. Goodman’s interests include image-guide radiation therapy and intensity modulated radiotherapy treatment planning for gastrointestinal cancers, as well as quality of life and late effects after radiotherapy.
Paul F. Lambert, Ph.D.
Professor of Oncology
University of Wisconsin, School of Medicine and Public Health
McArdle Laboratory for Cancer Research
Paul F. Lambert, Ph.D., received his undergraduate degree in biochemistry from the University of Massachusetts, and his Ph.D. in biochemistry from the University of Wisconsin-Madison. After pursuing postdoctoral training at the National Cancer Institute in Bethesda under Dr. Peter Howley on papillomavirus research, he joined the faculty in the McArdle Laboratory for Cancer Research (Dept of Oncology) at the University of Wisconsin, where he has been on the faculty for 20 years. There he heads a laboratory focused on the study of human papillomaviruses associated with cancers including anal, cervical and head/neck cancers. His lab has generated many mouse models for HPV-associated cancers including that of the anus. His lab’s research is primarily funded by the National Institutes of Health, which supports the lab with 5 research grants. In addition, he is the director of the Cancer Biology Graduate program at the University and is editor of Virology.
Karl Munger, Ph.D.
Department of Developmental, Molecular and Chemical Biology
Tufts University School of Medicine
Karl Munger Ph.D., obtained his degree in Biochemistry from the University of Zurich, Switzerland, followed by a postdoctoral fellowship at the National Cancer Institute in Bethesda, MD. He has been a faculty member at Harvard Medical School since 1993 and is currently an Associate Professor at the Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School. The research efforts of his laboratory are focused on delineating the molecular mechanisms of human papillomavirus (HPV)-associated cancer development. He has published more than 150 articles and has been recognized as one of the most highly cited scientists in the area of Microbiology by the Institute of Scientific Information (ISI). He serves on the Editorial Boards of Molecular Cancer, the International Journal of Cancer, Genes and Cancer, Virology and the Journal of Virology. He is also an Associate Editor for Cancer Biology and Therapy and a Section Editor for PLoS Pathogens. Dr. Munger has been regularly participating on grant review panels since 1995 and is currently a member of the Virology B study section (NIH). He has served as the basic science section chair of an advisory panel for the World Health Organization (WHO) and on a committee of the National Toxicology Program, which officially designated HPVs as carcinogenic agents in humans. His current research is supported by grants from the National Institutes of Health.
Joel Palefsky, M.D., C.M., F.R.C.P.(C)
Professor of Medicine
University of California, San Francisco
Division of Infectious Diseases
Joel Palefsky, M.D., C.M., F.R.C.P.(C)., completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University in 1989. He then joined the faculty at the University of California, San Francisco, where he remains to this day. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the Director of the world’s first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center. He has pioneered diagnostic and treatment methods for anal intraepithelial neoplasia (AIN) and has been an advocate for screening and treatment of AIN in high-risk populations to prevent anal cancer. He is the chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. He is a member of the board of the American Society for Colposcopy and Cervical Pathology (ASCCP) and co-chair of the ASCCP Special Populations Working Group. He is the author of over 220 publications.
Professor Margaret Stanley OBE
Professor of Epithelial Biology
Department of Pathology
University of Cambridge
Margaret has served on several research council committees and was a member of the Biology and Biotechnology Science Research Council from 2000-2003, as well as a member of the Spongiform Encephalopathies Advisory Committee (SEAC) that advised the UK government on prion diseases. In 2004, she was awarded the OBE for services to Virology, before being made a Fellow of the Academy of Medical Sciences in 2005. Her research interests have always concerned the biology of cervical epithelium and how and why cancer of the cervix develops. Her current research focuses on mechanisms of host defence and the development of vaccines and immunotherapies against human papillomaviruses (HPV), the cause of cervical cancer as well as a rising cause of throat cancers. She has published extensively in peer-reviewed journals, and has given 45 keynote or plenary presentations at national and international meetings on these topics in the last five years. She is currently on the Editorial Board of Sexually Transmitted Infections and Reviews in Medical Virology.
The Foundation thanks Hughes Hubbard & Reed, LLP for all of their guidance and support.
The Foundation thanks Stacey Billups, Allegra Crowther, Julia Dantchev, Yiling Loera and Deirdre Newman for generously supporting our organization with their graphic design and programming skills.